Argenica Therapeutics Limited (ASX:AGN) | ARG-007 (Xaranetide) Shows Significant Neuroprotection in Preclinical Concussion Study

MarketOpen Trading Titan Podcast | Argenica Therapeutics Limited (ASX: AGN) Episode: ARG-007 Shows Significant Neuroprotection in Preclinical Concussion Study Announcement Date: 16 July 2026 Argenica Therapeutics Limited has released positive preclinical data for its lead drug candidate, ARG-007 (xaranetide), from a repeated mild traumatic brain injury, or concussion, study conducted in collaboration with Curtin University and the Perron Institute for Neurological and Translational Science. The study found that a single intravenous dose of one milligram per kilogram, administered thirty minutes after injury, reduced multiple markers of secondary brain injury in a rodent model. According to the company, biomarkers including GFAP, Iba1, MnSOD and NF-L were reduced, with several returning to levels comparable with non-injured control animals. The reported effects lasted for up to eleven days after injury. Argenica states the findings are consistent with previously reported preclinical studies in stroke and traumatic brain injury and provide a scientific basis to explore concussion as a complementary indication alongside its lead stroke program. The announcement did not include any funding arrangements, commercial agreements or regulatory approvals. What to watch next: Any announcement from Argenica regarding the next steps to advance the development of ARG-007 in the concussion indication. This podcast is for information purposes only. Nothing in this episode constitutes financial advice. Listeners should conduct their own research and consider their own financial circumstances before making any investment decision.